Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDR | P35968 | 1/20 | 0.57 |
| ▸ | CNR2 | P34972 | 9/20 | 0.54 |
| ▸ | CNR1 | P21554 | 9/20 | 0.54 |
| ▸ | OPRM1 | P35372 | 2/20 | 0.53 |
| ▸ | ABHD12 | Q8N2K0 | 3/20 | 0.52 |
| ▸ | ABHD6 | Q9BV23 | 3/20 | 0.52 |
| ▸ | FAAH | O00519 | 2/20 | 0.52 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.52 |
| ▸ | LDHA | P00338 | 1/20 | 0.52 |
| ▸ | GLRA1 | P23415 | 1/20 | 0.52 |
| ▸ | GPR183 | P32249 | 1/20 | 0.52 |
| ▸ | DRD3 | P35462 | 1/20 | 0.52 |
| ▸ | ENPP2 | Q13822 | 1/20 | 0.52 |
| ▸ | GPR18 | Q14330 | 1/20 | 0.52 |
| ▸ | TRPM8 | Q7Z2W7 | 1/20 | 0.52 |
| ▸ | GPR55 | Q9Y2T6 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL279392 | 1.00 | KDR (0.57) | KDRCNR2CNR1OPRM1ABHD12 | |
| SCHEMBL5097376 | 1.00 | KDR (0.57) | KDRCNR2CNR1OPRM1ABHD12 | |
| SCHEMBL279759 | 1.00 | KDR (0.57) | KDRCNR2CNR1OPRM1ABHD12 | |
| SCHEMBL13998620 | 0.90 | KDR (0.58) | KDRCNR2CNR1OPRM1ABHD12 | |
| SCHEMBL11484472 | 0.86 | CNR2 (0.66) | KDRCNR2CNR1ABHD12ABHD6 | |
| SCHEMBL279382 | 0.86 | OPRM1 (0.55) | KDRCNR2CNR1OPRM1ABHD12 | |
| SCHEMBL279789 | 0.84 | CNR2 (0.58) | KDRCNR2CNR1ABHD12ABHD6 | |
| SCHEMBL5097828 | 0.84 | CNR2 (0.58) | KDRCNR2CNR1ABHD12ABHD6 | |
| SCHEMBL280014 | 0.84 | CNR2 (0.58) | KDRCNR2CNR1ABHD12ABHD6 | |
| SCHEMBL279664 | 0.83 | CNR1 (0.53) | KDRCNR2CNR1OPRM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080312224-A1 | Oxaphenanthrene Derivatives | MERCK PATENT GMBH (DE) | 2008-12-18 | — | — | US | disclosed |
| EP-1963299-A1 | OXAPHENANTHRENE DERIVATIVES | Merck Patent GmbH (DE) | 2008-09-03 | — | — | EP | disclosed |
| WO-2007079830-A1 | OXAPHENANTHRENE DERIVATIVES | MERCK PATENT GMBH (DE) | 2007-07-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080312224-A1 | Oxaphenanthrene Derivatives | CYP3A43, CYP1A1, CYP1A2 | KDR 1595/4885CNR2 1588/4885CNR1 1123/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.